Latest Interferon Stories
-- New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients -- In Phase 3 clinical trials, HOLKIRA
IES Diagnostics, Inc.’s New “Rapid Ebola Pre-Symptom Screening Test” designed for use before visible symptoms; can help redefine quarantine policies and ultimately save lives.
- Major regulatory milestone achieved toward approval in the European Union NORTH CHICAGO, Ill., Nov.
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) type 1 infection, TURQUOISE-I demonstrated sustained virologic response
- Results demonstrated high response rates in adult chronic hepatitis C genotype 4 patients without cirrhosis BOSTON, Nov.
-- Studies focused on patients where there is a high unmet need today or anticipated in the near future -- BOSTON, Nov.
--Expanded indication includes both treatment-naive and treatment-experienced adult patients with or without cirrhosis-- TITUSVILLE, N.J., Nov.
FLINT, Mich., Oct. 22, 2014 /PRNewswire/ -- U.S.
MOSCOW, October 21, 2014 /PRNewswire/ -- Hepatera Ltd and its development partner MYR GmbH announced today the results of clinical trials investigating Myrcludex B in patients
Data from 25 accepted abstracts include results from: NORTH CHICAGO, Ill., Oct.
Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...
- A gift; a largess; a gratuity; a present; a dole.